The patent filing and strong preclinical/translational data significantly de-risk the expansion of paxalisib into the adjuvant TNBC market, a large unmet need where ~1/3 of Stage II/III patients have residual disease post-standard therapy. Monitor for the company's upcoming development strategy update and potential partnership or financing to fund the next clinical trial.
Price Chart
Executive Summary
Kazia Therapeutics filed a provisional patent for a novel perioperative strategy using paxalisib to prevent metastatic recurrence in high-risk early-stage triple-negative breast cancer (TNBC). Preclinical data showed a 95% reduction in residual disease/local recurrence and a 40% reduction in lung metastatic burden, with translational ex vivo studies demonstrating 100% disruption of circulating tumor cell clusters. This expands paxalisib's potential addressable market beyond advanced/metastatic disease into the earlier-stage adjuvant setting, though all data are preclinical/translational and no clinical trial in this specific indication has been initiated.
Key Facts
- Filed a provisional patent for a novel perioperative strategy using paxalisib to prevent metastatic recurrence in high-risk early-stage TNBC.
- Preclinical model showed adjuvant paxalisib reduced residual disease and local recurrence by 95% (p<0.0001) and lung metastatic burden by 40% (p<0.027).
- Ex vivo translational studies on patient tumor samples showed paxalisib completely disrupted (100%) circulating tumor cell (CTC) clusters.
- Company is actively evaluating opportunities to broaden clinical development of paxalisib into earlier-stage TNBC and expects to provide additional details in the near term.
- Ongoing Phase Ib study in advanced metastatic TNBC has generated encouraging preliminary clinical and translational findings, including objective tumor responses with CTC cluster disruption.
Financial Impact
No financial figures reported. The patent filing and preclinical data expand the potential market opportunity for paxalisib into the adjuvant TNBC setting, but no clinical trial costs, revenue projections, or deal values were disclosed.
Risk Factors
- Preclinical and ex vivo data may not translate to clinical efficacy in humans.
- No clinical trial has been initiated in the adjuvant/perioperative TNBC setting; development is at a very early stage.
- Company will need additional capital to fund a new clinical trial in this indication, potentially causing dilution.
- Competing approaches (ADCs, additional cytotoxic therapies) are already in development for residual disease in TNBC.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-081982 |
| Document: ea029943501-6k_kazia.htm | 0001213900-26-081982 |
| Document: 0001213900-26-081982-index-headers.html | 0001213900-26-081982 |
| Document: 0001213900-26-081982-index.html | 0001213900-26-081982 |
| Document: 0001213900-26-081982.txt | 0001213900-26-081982 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $7.87 (−15.10%) |
Sep 22, 2026 4w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $7.87 (−27.93%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $7.87 (−37.59%) |
Aug 31, 2026 7w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $7.87 (+37.69%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $7.87 (−42.85%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $7.87 (+42.05%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $7.87 (−42.05%) |
Jul 28, 2026 12w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $7.87 (−37.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers